Research and Markets: Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review & Analysis, H2 2015
November 27 2015 - 9:18PM
Business Wire
Research and Markets
(http://www.researchandmarkets.com/research/fzmftp/acute_renal) has
announced the addition of the "Acute Renal Failure (ARF) (Acute
Kidney Injury) - Pipeline Review, H2 2015" report to their
offering.
This report provides comprehensive information on the
therapeutic development for Acute Renal Failure (ARF) (Acute Kidney
Injury), complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type, along with latest
updates, and featured news and press releases. It also reviews key
players involved in the therapeutic development for Acute Renal
Failure (ARF) (Acute Kidney Injury) and special features on
late-stage and discontinued projects.
Key Topics Covered:
- Snapshot of the global therapeutic landscape of Acute Renal
Failure (ARF) (Acute Kidney Injury)
- Key pipeline products under drug profile section which
includes, product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
- Key players involved in the therapeutics development for Acute
Renal Failure (ARF) (Acute Kidney Injury) and enlists all their
major and minor projects
- All dormant and discontinued pipeline projects
- All Acute Renal Failure (ARF) (Acute Kidney Injury) products
under development by companies and universities/research institutes
based on information derived from company and industry-specific
sources
- Pipeline products coverage based on various stages of
development ranging from pre-registration till discovery and
undisclosed stages
- Detailed assessment of monotherapy and combination therapy
pipeline projects
Benefits of this Report:
- Provides strategically significant competitor information,
analysis, and insights to formulate effective R&D development
strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain
competitive advantage
- Develop strategic initiatives by understanding the focus areas
of leading companies
- Identify and understand important and diverse types of
therapeutics under development for Acute Renal Failure (ARF) (Acute
Kidney Injury)
- Plan mergers and acquisitions effectively by identifying key
players of the most promising pipeline
- Devise corrective measures for pipeline projects by
understanding Acute Renal Failure (ARF) (Acute Kidney Injury)
pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects
to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued
projects and understanding the factors that drove them from
pipeline
Companies Mentioned Include:
- A1M Pharma AB
- Adrenomed AG
- Am-Pharma B.V.
- Angion Biomedica Corp.
- Bolder Biotechnology, Inc.
- Cellmid Limited
- Complexa, Inc.
- DiaMedica Inc.
- Digna Biotech, S.L.
- DURECT Corporation
- F. Hoffmann-La Roche Ltd.
- STATegics, Inc.
- Thrasos, Inc.
- Torrent Pharmaceuticals Limited
For more information visit
http://www.researchandmarkets.com/research/fzmftp/acute_renal
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151127005414/en/
Research and MarketsLaura Wood, Senior
Managerpress@researchandmarkets.comFor E.S.T Office Hours Call
1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT
Office Hours Call +353-1-416-8900U.S. Fax: 646-607-1907Fax (outside
U.S.): +353-1-481-1716Sector: Pharmaceuticals